Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Dec 17;110(51):E4987-96.
doi: 10.1073/pnas.1308313110. Epub 2013 Nov 25.

The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

Lina Josefsson  1 , Susanne von Stockenstrom, Nuno R Faria, Elizabeth Sinclair, Peter Bacchetti, Maudi Killian, Lorrie Epling, Alice Tan, Terence Ho, Philippe Lemey, Wei Shao, Peter W Hunt, Ma Somsouk, Will Wylie, Daniel C Douek, Lisa Loeb, Jeff Custer, Rebecca Hoh, Lauren Poole, Steven G Deeks, Frederick Hecht, Sarah Palmer
Affiliations
Clinical Trial

The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

Lina Josefsson et al. Proc Natl Acad Sci U S A. .

Abstract

The source and dynamics of persistent HIV-1 during long-term combinational antiretroviral therapy (cART) are critical to understanding the barriers to curing HIV-1 infection. To address this issue, we isolated and genetically characterized HIV-1 DNA from naïve and memory T cells from peripheral blood and gut-associated lymphoid tissue (GALT) from eight patients after 4-12 y of suppressive cART. Our detailed analysis of these eight patients indicates that persistent HIV-1 in peripheral blood and GALT is found primarily in memory CD4(+) T cells [CD45RO(+)/CD27((+/-))]. The HIV-1 infection frequency of CD4(+) T cells from peripheral blood and GALT was higher in patients who initiated treatment during chronic compared with acute/early infection, indicating that early initiation of therapy results in lower HIV-1 reservoir size in blood and gut. Phylogenetic analysis revealed an HIV-1 genetic change between RNA sequences isolated before initiation of cART and intracellular HIV-1 sequences from the T-cell subsets after 4-12 y of suppressive cART in four of the eight patients. However, evolutionary rate analyses estimated no greater than three nucleotide substitutions per gene region analyzed during all of the 4-12 y of suppressive therapy. We also identified a clearly replication-incompetent viral sequence in multiple memory T cells in one patient, strongly supporting asynchronous cell replication of a cell containing integrated HIV-1 DNA as the source. This study indicates that persistence of a remarkably stable population of infected memory cells will be the primary barrier to a cure, and, with little evidence of viral replication, this population could be maintained by homeostatic cell proliferation or other processes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Phylogenetic analysis of viral sequences from plasma isolated before the initiation of cART and cells isolated from peripheral blood and GALT after several years of suppressive cART. ML trees of sequences from pretherapy plasma (gray filled circles), on-therapy plasma (red filled circles), peripheral blood [all memory (blue filled triangles), central/transitional memory (blue filled squares), effector memory (blue open squares), and naïve (blue open circles) T cells], and GALT [central/transitional memory (green filled squares), effector memory (green open squares), and naïve (green open circles) T cells] from a subset of patients initiating antiviral therapy during acute/early HIV-1 infection (patients 3 and 5) (A and B), and during chronic HIV-1 infection (patients 7 and 8) (C and D: red circles indicate identical sequences isolated from different cells). Patient 7 initiated therapy in chronic infection and had identical clonal HIV-1 sequences containing a large 380-bp deletion (C). The trees representing the sequences isolated from patients 1, 2, 4, and 6 are in Fig. S3.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Deeks SG, et al. International AIDS Society Scientific Working Group on HIV Cure Towards an HIV cure: A global scientific strategy. Nat Rev Immunol. 2012;12(8):607–614. - PMC - PubMed
    1. Dornadula G, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282(17):1627–1632. - PubMed
    1. Havlir DV, et al. Gilead 903 Study Team Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis. 2005;191(7):1164–1168. - PubMed
    1. Maldarelli F, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3(4):e46. - PMC - PubMed
    1. Zhang L, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340(21):1605–1613. - PubMed

Publication types

MeSH terms